The stock of Lilly(Eli) & Co (NYSE:LLY) last traded at $588.54, down -3.65% from the previous session.
Data from the available sources indicates that Lilly(Eli) & Co (NYSE:LLY) is covered by 30 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $722.00 and a low of $430.00, we find $650.00. Given the previous closing price of $610.82, this indicates a potential upside of 6.41 percent. LLY stock price is now 2.00% away from the 50-day moving average and 28.95% away from the 200-day moving average. The market capitalization of the company currently stands at $558.71B.
In total, 5 analysts have assigned it a hold rating, and 19 have given it a buy rating. Brokers who have rated the stock have averaged $626.17 as their price target over the next twelve months.
With the price target of $535, Deutsche Bank recently initiated with Hold rating for Lilly(Eli) & Co (NYSE: LLY).
In other news, Zakrowski Donald A, SVP, Finance, & CAO sold 670 shares of the company’s stock on Nov 06. The stock was sold for $382,637 at an average price of $571.10. Upon completion of the transaction, the SVP, Finance, & CAO now directly owns 4,708 shares in the company, valued at $2.77 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 11, 10% Owner LILLY ENDOWMENT INC sold 215,000 shares of the business’s stock. A total of $130,169,879 was realized by selling the stock at an average price of $605.44. This leaves the insider owning 99,768,810 shares of the company worth $58.72 billion. Insiders disposed of 3,258,909 shares of company stock worth roughly $1.92 billion over the past 1 year. A total of 10.68% of the company’s stock is owned by insiders.
With an opening price of $610.88 on Wednesday morning, Lilly(Eli) & Co (NYSE: LLY) set off the trading day. During the past 12 months, Lilly(Eli) & Co has had a low of $309.20 and a high of $629.97. As of last week, the company has a debt-to-equity ratio of 1.80, a current ratio of 1.05, and a quick ratio of 0.82. According to the stock market information, the enterprise value for the company is $576.38B, which is based on a 108.63 price-to-earnings ratio, a 3.86 price-to-earnings-growth ratio, and a beta of 0.34. The fifty day moving average price for LLY is $577.55 and a two-hundred day moving average price translates $457.64 for the stock.
The latest earnings results from Lilly(Eli) & Co (NYSE: LLY) was released for Sep, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $0.1, beating analysts’ expectations of -$0.13 by 0.23. This compares to $1.61 EPS in the same period last year. The net profit margin was 15.55% and return on equity was 46.86% for LLY. The company reported revenue of $9.5 billion for the quarter, compared to $6.94 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 36.84 percent. For the current quarter, analysts expect LLY to generate $8.94B in revenue.
Lilly(Eli) & Co(LLY) Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin’s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.